Document:

<PAGE>

                            CLINICAL TRIAL AGREEMENT

     Agreement made this 27th day of July, 1999 ("Effective Date") between The
General Hospital Corporation, a not-for-profit corporation doing business as
Massachusetts General Hospital, having a principal place of business at Fruit
Street, Boston, Massachusetts 02114 ("General"), Charles Taylor, MD, Department
of Dematology, Massachusetts General Hospital, Boston, Massachusetts 02114
("Principal Investigator") and Laser Photonics, Inc. a corporation having an
office at 2431 Impala Drive, Carlsbad, CA 92008 ("Company").

     All of the parties to this Agreement share a common mission of improving
the public health by engaging in research for the purpose of discovering and
making available to the public new and improved medical drugs and devices. In
connection with this mission, Company desires to have further clinical research
conducted on its device described below. General and Principal Investigator,
having particular expertise and opportunity, desire to provide this research.
Accordingly, the parties agree as follows.

SECTION 1: STUDY PERFORMANCE

     1.1  PROTOCOL Subject to approval of the Study pursuant to Section 1.2
below, Principal Investigator agrees to conduct to the extent funds are made
available hereunder a clinical study of a 308nm Excimer Laser manufactured by
Acculase, Inc., a subsidiary of Laser Photonics, Inc. (hereinafter referred to
as the "Study Device") in accordance with the study protocol entitled "Pilot
Study to Determine the Safety and Efficacy of the 308 Excimer Laser for
Treatment of Scalp Psoriasis", a copy of which is attached hereto as Exhibit A
(hereinafter referred to as the "Study"). In the event of any conflict between
Exhibit A and the provisions of this Agreement, the provisions of this Agreement
shall govern.

     1.2  STUDY REVIEW Principal Investigator shall conduct the Study at General
with the prior approval and ongoing review of all appropriate and necessary
review authorities and in accordance with all applicable federal, state and
local laws and regulations. Principal Investigator shall provide Company with
written evidence of review and approval of this Study by General's Institutional
Review Board ("IRB") prior to the initiation of the Study and shall inform
Company of the IRB's continuing review promptly after such review takes place,
which shall be at least once per year. All volunteers shall meet the legal age
requirements of the Commonwealth of Massachusetts, the state in which the Study
is to be conducted.

     1.3  STUDY DEVICE Company shall provide General, at no charge, with
quantities of the Study Device required for the Study. The General and Principal
Investigator shall safeguard such Study Device with the degree of care used for
its own property. Upon completion or termination of the Study and upon Company's
request, General shall return or otherwise dispose of any remaining Study Device
in accordance with Company's instructions. General and Principal Investigator
shall not use any Study Device for any purpose other than the Study, unless
otherwise agreed.

                                       1
<PAGE>

SECTION 2: RESULTS OF THE STUDY

     2.1  OWNERSHIP OF RECORDS, DATA AND INTELLECTUAL PROPERTY Company shall own
its case report forms and the data resulting from the Study. General shall own
its medical records, research notebooks and related documentation and any
intellectual property resulting from the Study subject to the option granted to
Company to license Inventions in Section 2.3 below. General shall have the right
to use the data for research, educational and patient care purposes as well as
to comply with any federal, state or local government laws or regulations.
Notwithstanding the above, Company shall not use any patient names, identifying
information, photographs, or other likenesses without first obtaining the
specific written informed consent of such patient for such use.

     2.2  PUBLICATION The Principal Investigator shall be free to publish the
results of the Study subject only to the provisions of Section 3 regarding
Company's Proprietary Information. The Principal Investigator shall furnish
Company with a copy of any proposed publication for review and comment prior to
submission for publication, at least thirty (30) days prior to submission for
manuscripts and at least seven (7) days prior to submission for abstracts. At
the expiration of such thirty (30) day or seven (7) day period, Principal
Investigator may proceed with submission for publication provided, however, that
upon notice by Company that Company reasonably believes a patent application
claiming an Invention (as defined in Section 2.3) should be filed prior to such
publication, such publication shall be delayed for an additional thirty (30)
days or until any patent application or applications have been filed, whichever
shall first occur. In no event shall the submission of such publication of
results be delayed for more than sixty (60) days for manuscripts and for more
than thirty-seven (37) days for abstracts from the date such proposed
publication was received by Company; at the end of said sixty (60) or
thirty-seven (37) days, the Principal Investigator shall be free to publish such
results as proposed.

     2.3  INVENTIONS

          (a)  Subject to the terms of Paragraphs 2.3 (b)-(g) below, the
Principal Investigator and any other General personnel performing the Study
under his or her direction who makes an invention which constitutes a new use of
or modification to the Study Device in the performance of the Study
("Invention") shall promptly report and assign such Invention to General.
General shall promptly disclose in writing any Inventions to Company. Within
thirty (30) days of such disclosure, Company shall notify General in writing if
it wishes General to file a patent application claiming the Invention.

          (b)  in the event of joint inventorship under the Study of a new use
of or modification of the Study Device between Investigators and/or personnel
from General and personnel from Company ("Joint Invention"), such Investigators
and/or personnel shall assign all of their rights, title and interest in the
Joint Invention to General and such personnel from Company shall assign all of
their rights, title and interest in the Joint Invention to Company, and the
Joint Invention shall be deemed jointly owned. Promptly

                                       2
<PAGE>

after disclosure of the invention, the parties shall then mutually agree as to
whether an application for the Joint Invention shall be filed

          (c)  As to any patent applications prepared and/or filed under either
paragraphs (a) or (b) above, Company shall have and is hereby given by General
an exclusive option, for a period of ninety (90) days following the disclosure
of such invention, to seek either (1) a worldwide, exclusive or non-exclusive
license for inventions in which General personnel are the, sole named inventors;
or (2) a worldwide, exclusive license for General's rights in any Joint
Inventions. Exercise of Company's option shall be provided in writing to
General.

          (d)  In the event Company exercises its option under Paragraph 2.3(c)
above, the Parties shall have ninety (90) days from the date of Company's notice
to negotiate in good faith a license agreement containing license terms standard
for agreements between universities and industry, which may include payment of
reasonable royalties and other compensation to General, objective, time-limited
due diligence provisions for the development, commercialization and marketing of
a product embodying the invention and product liability indemnification and
insurance requirements which are acceptable to General's liability insurance
carrier. In the event the parties are unable to reach agreement on the terms of
a license under this paragraph, General shall then have the right to license its
rights to any third party, provided however, that no license to a third party
shall be agreed to by General on terms more favorable than those terms last
offered to Company.

          (e)  Notwithstanding the above paragraphs of this Section 2, in the
event there is an invention under the Study, either solely by General personnel
or jointly by General and Company personnel, that is: (1) directed to an optimal
dosage, protocol and/or device configuration for treating psoriasis using
ultraviolet radiation in the manner such radiation is generated by Company's
Study Device and (2) that would not come within the definition of "Patent Right"
as set forth in the License Agreement dated November 26, 1997 between the
parties, it is agreed that Company shall be given a paid up worldwide exclusive
license to such invention and that payment by Company for the Study and for all
patent preparation and filing costs for such invention shall constitute, the
consideration for the paid up license.

          (f)  It is agreed that for any patent application under which Company
is the licensee, Company shall pay all reasonable fees and costs associated with
the, preparation and prosecution of such application, provided however, that the
parties shall mutually select the attorneys for such application and that
General shall keep Company promptly apprised of all proceedings in connection
with the application and Company shall have the right to review and approve all
submissions made during said filing and prosecution.

          (g)  In the event the Parties do not come to an agreement as to the
terms of a license under Paragraphs 2-3 (a)-(d), Company shall no longer have
responsibility

                                       3
<PAGE>

to fund any further fees and costs associated with the filing and prosecution of
the application, and, in the event General enters into an agreement with third
party for such application, Company shall be reimbursed for the fees and costs
Company previously paid.

     2.4  USE OF NAME Except for disclosure by General of Company's support for
the Study in publications, no party to this Agreement shall use the name of any
other party or of any staff member, employee or student of any other party or
any adaptation, acronym or name by which any party is commonly known, in any
advertising, promotional or sales literature or in any publicity without the
prior written approval of the party or individual whose name is to be used. For
General, such approval shall be obtained from the Director of Public Affairs and
for Company, from Mr. Chaim Markheim.

     2.5  STUDY RECORDS General shall make Study records available to Company
representatives upon request for comparison with case report forms. General
shall also make such records available upon reasonable request for review by
representatives of the U.S. Food and Drug Administration. General shall retain
records of the Study including either the original or a copy of all volunteer
consent forms in conformance with applicable federal regulations. Company shall
notify Principal Investigator of the date a premarket approval application (PMA)
is approved for the Study Device; or if the application is not approved, Company
shall notify Principal Investigator when all clinical investigations have been
discontinued and the FDA notified.

SECTION 3: COMPANY PROPRIETARY INFORMATION

     3.1  It is anticipated that in the performance of the Study, Company shall
provide to General, Principal Investigator and other General personnel who are
designated in writing by the Principal Investigator as being authorized to
receive Proprietary Information and who agree in writing to the following
confidentiality obligations (each such institution or person individually
referred to in this Section 3.1 as "a Recipient" and collectively as
"Recipients"), or shall give Recipients access to, certain information which
Company considers proprietary. The rights and obligations of the parties with
respect to such information are as follows:

     (a)  For the purposes of this Agreement, "Proprietary Information" refers
to information of any kind which is disclosed by Company to a Recipient and
which, by appropriate marking, is identified as confidential and proprietary at
the time of disclosure. In the event that proprietary information must be
provided visually or orally, obligations of confidence shall attach only to that
information which is confirmed by Company in writing within ten (10) working
days as being confidential.

     (b)  For a period of five (5) years after the Effective Date of this
Agreement, each Recipient agrees to use reasonable efforts, no less than the
protection given their

                                       4
<PAGE>

own confidential information, to use Proprietary Information received from
Company and accepted by that Recipient only in accordance with this
Section 3.1(b).

     (i)  Each Recipient shall use Company's Proprietary Information solely for
     the purposes of conducting the Study, obtaining any required review of the
     Study or its conduct, or ensuring proper medical treatment of any patient
     or subject. Each Recipient agrees to make Proprietary Information available
     only to those employees and students of General who require access to it in
     the performance of this Study and to inform them of the confidential nature
     of such information.

     (ii) Except as provided in subsection 3.1(b)(i), each Recipient shall keep
     all Proprietary Information confidential unless Company gives specific
     written consent for release.

     (iii) If any Recipient becomes aware of any disclosure not authorized
     hereunder, that Recipient shall notify Company and take reasonable steps to
     prevent any further disclosure or unauthorized use.

     (c)  No Recipient shall be required to treat any information as Proprietary
Information under this Agreement in the event: (i) it is publicly available
prior to the date of the Agreement or becomes publicly available thereafter
through no wrongful act of any Recipient; (ii) it was known to any Recipient
prior to the date of disclosure or becomes known to any Recipient thereafter
from a third party having an apparent bona fide right to disclose the
information; (iii) it is disclosed by any Recipient in accordance with the terms
of Company's prior written approval; (iv) it is disclosed by Company without
restriction on further disclosure; (v) it is independently developed by any
Recipient; or, (vi) any Recipient is obligated to produce it pursuant to an
order of a court of competent jurisdiction or a facially valid administrative,
Congressional or other subpoena, provided that the Recipient subject to the
order or subpoena (A) promptly notifies Company and (B) cooperates reasonably
with Company's efforts to contest or limit the scope of such order.

SECTION 4: BUDGET

     4.1  Company agrees to support this Study with a research grant of One
hundred seventy-five thousand, two hundred fifty dollars ($175,250) which
includes indirect costs in the amount of Thirty-five thousand fifty dollars
($35,050) computed at a rate of 25% of total direct costs, payable to General as
follows:

     Eighty-seven thousand, six hundred twenty-five dollars ($87,625) upon
execution of this Agreement;

     Forty-three thousand, eight hundred twelve dollars ($43,812) upon
enrollment of ten (10) subjects; and,

                                       5
<PAGE>

         Forty-three thousand, eight hundred twelve dollars ($43,812)
Forty-three thousand eight hundred twelve dollars ($43,812) upon completion of a
total of twenty (20) subjects and submission of all completed case report forms.

         4.2 Checks should be made payable to "The General Hospital Corporation"
and sent, along with a letter indicating the name of the Principal Investigator
and the specific clinical trial agreement for which the funds are intended, to:

                      Financial Control Coordinator
                      Research Finance
                      Massachusetts General Hospital
                      Thirteenth Street, Building 149, Suite 1115
                      Charlestown, MA  02129

SECTION 5: TERM AND TERMINATION

     5.1  The term of this Agreement shall be until the completion of the Study,
which is anticipated to be one (1) year from the Effective Date, unless
terminated in accordance with Section 5.2.

     5.2. Any party hereto shall have the right to terminate the Study and this
Agreement at any time upon thirty (30) days prior written notice thereof to the
other parties, except that any party may terminate this Agreement immediately
upon written notice to the other parties if necessary to protect the health,
welfare or safety of any Study subject.

     5.3  In the event of termination, the amount of the research grant by
Company to support the Study shall be appropriately prorated to allow General to
recover reasonable costs and noncancellable commitments incurred, including
without limitation, termination salary costs of any of General's employees
released as a result of such termination.

     5.4  The obligations of the parties under Sections 2, 3 and 6 shall survive
the termination or expiration of this Agreement.

SECTION 6: INDEMNIFICATION AND INSURANCE

     6.1  INDEMNIFICATION (a) Company shall indemnify, defend and hold harmless
General and its trustees, officers, medical and professional staff, employees,
and agents and their respective successors, heirs and assigns (the
"Indemnitees"), against any liability, damage, loss or expense (including
reasonable attorney's fees and expenses of litigation) incurred by or imposed
upon the Indemnitees or any one of them in connection with any claims, suits,
actions, demands or judgments arising out of any side effect, adverse reaction,
illness, or injury occurring to any person as a result of his or her involvement
in the Study.

                                       6
<PAGE>

     (b)  Company's indemnification under (a) above shall not apply to any
liability, damage, loss or expense to the extent that it is directly
attributable to: (i) the negligent activities, reckless misconduct or
intentional misconduct of the Indemnitees; or (ii) failure of the Indemnitees to
adhere to the terms of the protocol for the Study.

     (c)  Company agrees, at its own expense, to provide attorneys reasonably
acceptable to General to defend against any actions brought or filed against any
party indemnified hereunder with respect to the subject of the indemnity
contained herein, whether or not such actions are rightfully brought.

     (d)  Company also agrees to reimburse General for the costs of the care and
treatment of any illness or injury to a subject resulting from his or her
participation in the Study to the extent that such costs are not covered by the
subject's medical or hospital insurance or governmental programs providing such
coverage.

     6.2  INSURANCE (a) Company shall, at its sole cost and expense, procure and
maintain commercial general liability insurance or equivalent self-insurance in
amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate.
Such commercial general liability insurance or equivalent self-insurance shall
provide contractual liability coverage for Company's indemnification under
Section 6.1 of this Agreement.

     (b)  Company shall provide General with written evidence of such insurance
prior to the commencement of the Study. Company shall provide General with
written notice at least fifteen (15) days prior to the cancellation, non-renewal
or material change, in such insurance; if Company does not obtain replacement
insurance providing comparable coverage within such fifteen (15) day period,
General shall have the right to terminate this Agreement effective at the end of
such fifteen (15) day period without notice of any additional waiting periods.

SECTION 7: MISCELLANEOUS

     7.1  The terms of this Agreement can be modified only by a writing which is
signed by General, Principal Investigator and Company.

     7.2  The provisions of this Agreement shall be interpreted under the laws
of the Commonwealth of Massachusetts, regardless of the choice of law rules of
any jurisdiction.

     7.3  No party to this Agreement may assign its obligations hereunder
without the prior written consent of the other parties.

     7.4  This Agreement constitutes the entire understanding between the
parties, and supersedes and replaces all prior agreements, understandings,
writings and discussions between the parties, with respect to the subject matter
of this Agreement.

                                       7
<PAGE>

           IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed as of the day and year first above written.

LASER PHOTONICS, INC.                   THE GENERAL HOSPITAL CORPORATION
                                           (Federal Tax ID No.: 042 697 983)

BY: /s/ Chaim Markheim              By:  /s/ Nikki J. Zapol
    -----------------------------        ----------------------------
TITLE:  COO/CFO                     TITLE: Director, Office of Corporate
                                           Sponsored Research and Licensing

DATE:    8/4/99                     DATE:  8/9/99

                                       8<PAGE>

                            CLINICAL TRIAL AGREEMENT

     Agreement made this 27th day of July, 1999 ("Effective Date") between The
General Hospital Corporation, a not-for-profit corporation doing business as
Massachusetts General Hospital, having a principal place of business at Fruit
Street, Boston, Massachusetts 02114 ("General"), Charles Taylor, MD, Department
of Dematology, Massachusetts General Hospital, Boston, Massachusetts 02114
("Principal Investigator") and Laser Photonics, Inc. a corporation having an
office at 2431 Impala Drive, Carlsbad, CA 92008 ("Company").

     All of the parties to this Agreement share a common mission of improving
the public health by engaging in research for the purpose of discovering and
making available to the public new and improved medical drugs and devices. In
connection with this mission, Company desires to have further clinical research
conducted on its device described below. General and Principal Investigator,
having particular expertise and opportunity, desire to provide this research.
Accordingly, the parties agree as follows.

SECTION 1: STUDY PERFORMANCE

     1.1 PROTOCOL Subject to approval of the Study pursuant to Section 1.2
below, Principal Investigator agrees to conduct to the extent funds are made
available hereunder a clinical study of a 308nm Excimer Laser manufactured by
Acculase, Inc., a subsidiary of Laser Photonics, Inc. (hereinafter referred to
as the "Study Device") in accordance with the study protocol entitled "308 nm
Excimir Laser for the Treatment of Plaque Psoriasis (4MED/6MED)", a copy of
which is attached hereto as Exhibit A (hereinafter referred to as the "Study").
In the event of any conflict between Exhibit A and the provisions of this
Agreement, the provisions of this Agreement shall govern.

     1.2 STUDY REVIEW Principal Investigator shall conduct the Study at General
with the prior approval and ongoing review of all appropriate and necessary
review authorities and in accordance with all applicable federal, state and
local laws and regulations. Principal Investigator shall provide Company with
written evidence of review and approval of this Study by General's Institutional
Review Board ("IRB") prior to the initiation of the Study and shall inform
Company of the IRB's continuing review promptly after such review takes place,
which shall be at least once per year. All volunteers shall meet the legal age
requirements of the Commonwealth of Massachusetts, the state in which the Study
is to be conducted.

     1.3 STUDY DEVICE Company shall provide General, at no charge, with
quantities of the Study Device required for the Study. The General and Principal
Investigator shall safeguard such Study Device with the degree of care used for
its own property. Upon completion or termination of the Study and upon Company's
request, General shall return or otherwise dispose of any remaining Study Device
in accordance with Company's instructions. General and Principal Investigator
shall not use any Study Device for any purpose other than the Study, unless
otherwise agreed.

                                       1
<PAGE>

SECTION 2:  RESULTS OF THE STUDY

     2.1 OWNERSHIP OF RECORDS, DATA AND INTELLECTUAL PROPERTY Company shall own
its case report forms and the data resulting from the Study. General shall own
its medical records, research notebooks and related documentation and any
intellectual property resulting from the Study subject to the option granted to
Company to license Inventions in Section 2.3 below. General shall have the right
to use the data for research, educational and patient care purposes as well as
to comply with any federal, state or local government laws or regulations.
Notwithstanding the above, Company shall not use any patient names, identifying
information, photographs, or other likenesses without first obtaining the
specific written informed consent of such patient for such use.

     2.2 PUBLICATION The Principal Investigator shall be free to publish the
results of the Study subject only to the provisions of Section 3 regarding
Company's Proprietary Information. The Principal Investigator shall furnish
Company with a copy of any proposed publication for review and comment prior to
submission for publication, at least thirty (30) days prior to submission for
manuscripts and at least seven (7) days prior to submission for abstracts. At
the expiration of such thirty (30) day or seven (7) day period, Principal
Investigator may proceed with submission for publication provided, however, that
upon notice by Company that Company reasonably believes a patent application
claiming an Invention (as defined in Section 2.3) should be filed prior to such
publication, such publication shall be delayed for an additional thirty (30)
days or until any patent application or applications have been filed, whichever
shall first occur. In no event shall the submission of such publication of
results be delayed for more than sixty (60) days for manuscripts and for more
than thirty-seven (37) days for abstracts from the date such proposed
publication was received by Company; at the end of said sixty (60) or
thirty-seven (37) days, the Principal Investigator shall be free to publish such
results as proposed.

     2.3 INVENTIONS

         (a) Subject to the terms of Paragraphs 2.3 (b)-(g) below, the Principal
Investigator and any other General personnel performing the Study under his or
her direction who makes an invention which constitutes a new use of or
modification to the Study Device in the performance of the Study ("Invention")
shall promptly report and assign such Invention to General. General shall
promptly disclose in writing any Inventions to Company. Within thirty (30) days
of such disclosure, Company shall notify General in writing if it wishes General
to file a patent application claiming the Invention.

         (b) In the event of joint inventorship under the Study of a new use of
or modification of the Study Device between Investigators and/or personnel from
General and personnel from Company ("Joint Invention"), such Investigators
and/or personnel shall assign all of their rights, title and interest in the
Joint Invention to General and such personnel from Company shall assign all of
their rights, title and interest in the Joint Invention to Company, and the
Joint Invention shall be deemed jointly owned. Promptly

                                       2
<PAGE>

after disclosure of the invention, the parties shall then mutually agree as to
whether an application for the Joint Invention shall be filed.

         (c) As to any patent applications prepared and/or filed under either
paragraphs (a) or (b) above, Company shall have and is hereby given by General
an exclusive option, for a period of ninety (90) days following the disclosure
of such invention, to seek either (1) a worldwide., exclusive or non-exclusive
license for inventions in which General personnel are the, sole named inventors;
or (2) a worldwide, exclusive license for General's rights in any Joint
Inventions. Exercise of Company's option shall be provided in writing to
General.

         (d) In the event Company exercises its option under Paragraph 2.3(c)
above, the Parties shall have ninety (90) days from the date of Company's notice
to negotiate in good faith a license agreement containing license terms standard
for agreements between universities and industry, which may include payment of
reasonable royalties and other compensation to General, objective, time-limited
due diligence provisions for the development, commercialization and marketing of
a product embodying the invention and product liability indemnification and
insurance requirements which are acceptable to General's liability insurance
carrier. In the event the parties are unable to reach agreement on the terms of
a license under this paragraph, General shall then have the right to license its
rights to any third party, provided however, that no license to a third party
shall be agreed to by General on terms more favorable than those terms last
offered to Company.

         (e) Notwithstanding the above paragraphs of this Section 2, in the
event there is an invention under the Study, either solely by General personnel
or jointly by General and Company personnel, that is: (1) directed to an optimal
dosage, protocol and/or device configuration for treating psoriasis using
ultraviolet radiation in the manner such radiation is generated by Company's
Study Device and (2) that would not come within the definition of "Patent Right"
as set forth in the License Agreement dated November 26, 1997 between the
parties, it is agreed that Company shall be given a paid up worldwide exclusive
license to such invention and that payment by Company for the Study and for all
patent preparation and filing costs for such invention shall constitute, the
consideration for the paid up license.

         (f) It is agreed that for any patent application under which Company is
the licensee, Company shall pay all reasonable fees and costs associated with
the, preparation and prosecution of such application, provided however, that the
parties shall mutually select the attorneys for such application and that
General shall keep Company promptly apprised of all proceedings in connection
with the application and Company shall have the right to review and approve all
submissions made during said filing and prosecution.

         (g) In the event the Parties do not come to an agreement as to the
terms of a license under Paragraphs 2-3 (a) - (d), Company shall no longer have
responsibility

                                       3
<PAGE>

to fund any further fees and costs associated with the filing and prosecution of
the application, and, in the event General enters into an agreement with third
party for such application, Company shall be reimbursed for the fees and costs
Company previously paid.

     2.4 USE OF NAME Except for disclosure by General of Company's support for
the Study in publications, no party to this Agreement shall use the name of any
other party or of any staff member, employee or student of any other party or
any adaptation, acronym or name by which any party is commonly known, in any
advertising, promotional or sales literature or in any publicity without the
prior written approval of the party or individual whose name is to be used. For
General, such approval shall be obtained from the Director of Public Affairs and
for Company, from Mr. Chaim Markheim.

     2.5 STUDY RECORDS General shall make Study records available to Company
representatives upon request for comparison with case report forms. General
shall also make such records available upon reasonable request for review by
representatives of the U.S. Food and Drug Administration. General shall retain
records of the Study including either the original or a copy of all volunteer
consent forms in conformance with applicable federal regulations. Company shall
notify Principal Investigator of the date a premarket approval application (PMA)
is approved for the Study Device; or if the application is not approved, Company
shall notify Principal Investigator when all clinical investigations have been
discontinued and the FDA notified.

SECTION 3: COMPANY PROPRIETARY INFORMATION

     3.1 It is anticipated that in the performance of the Study, Company shall
provide to General, Principal Investigator and other General personnel who are
designated in writing by the Principal Investigator as being authorized to
receive Proprietary Information and who agree in writing to the following
confidentiality obligations (each such institution or person individually
referred to in this Section 3.1 as "a Recipient" and collectively as
"Recipients"), or shall give Recipients access to, certain information which
Company considers proprietary. The rights and obligations of the parties with
respect to such information are as follows:

         (a) For the purposes of this Agreement, "Proprietary Information"
refers to information of any kind which is disclosed by Company to a Recipient
and which, by appropriate marking, is identified as confidential and proprietary
at the time of disclosure. In the event that proprietary information must be
provided visually or orally, obligations of confidence shall attach only to that
information which is confirmed by Company in writing within ten (10) working
days as being confidential.

         (b) For a period of five (5) years after the Effective Date of this
Agreement, each Recipient agrees to use reasonable efforts, no less than the
protection given their

                                       4
<PAGE>

own confidential information, to use Proprietary Information received from
Company and accepted by that Recipient only in accordance with this Section
3.1(b).

         (i) Each Recipient shall use Company's Proprietary Information solely
         for the purposes of conducting the Study, obtaining any required review
         of the Study or its conduct, or ensuring proper medical treatment of
         any patient or subject. Each Recipient agrees to make Proprietary
         Information available only to those employees and students of General
         who require access to it in the performance of this Study and to inform
         them of the confidential nature of such information.

         (ii) Except as provided in subsection 3.1(b)(i), each Recipient shall
         keep all Proprietary Information confidential unless Company gives
         specific written consent for release.

         (iii) If any Recipient becomes aware of any disclosure not authorized
         hereunder, that Recipient shall notify Company and take reasonable
         steps to prevent any further disclosure or unauthorized use.

         (c) No Recipient shall be required to treat any information as
Proprietary Information under this Agreement in the event: (i) it is publicly
available prior to the date of the Agreement or becomes publicly available
thereafter through no wrongful act of any Recipient; (ii) it was known to any
Recipient prior to the date of disclosure or becomes known to any Recipient
thereafter from a third party having an apparent bona fide right to disclose the
information; (iii) it is disclosed by any Recipient in accordance with the terms
of Company's prior written approval; (iv) it is disclosed by Company without
restriction on further disclosure; (v) it is independently developed by any
Recipient; or, (vi) any Recipient is obligated to produce it pursuant to an
order of a court of competent jurisdiction or a facially valid administrative,
Congressional or other subpoena, provided that the Recipient subject to the
order or subpoena (A) promptly notifies Company and (B) cooperates reasonably
with Company's efforts to contest or limit the scope of such order.

SECTION 4:  BUDGET

     4.1 Company agrees to support this Study with a research grant of Three
hundred thirty-eight thousand, four hundred thirty-eight dollars ($338,438)
which includes indirect costs in the amount of Sixty-seven thousand, six hundred
eighty-eight dollars ($67,688) computed at a rate of 25% of total direct costs,
payable to General as follows:

     One hundred sixty-nine thousand, two hundred nineteen dollars ($169,219)
upon execution of this Agreement;

     Eighty-four thousand, six hundred nine dollars and fifty cents ($84,609.50)
upon enrollment of twelve (12) subjects; and,

                                       5
<PAGE>

     Eighty-four thousand, six hundred nine dollars and fifty cents
($84,609.50) upon completion of a total of twenty (20) subjects and submission
of all completed case report forms.

     4.2 Checks should be made payable to "The General Hospital Corporation" and
sent, along with a letter indicating the name of the Principal Investigator and
the specific clinical trial agreement for which the funds are intended, to:

                           Financial Control Coordinator
                           Research Finance
                           Massachusetts General Hospital
                           Thirteenth Street, Building 149, Suite 1115
                           Charlestown, MA  02129

SECTION 5:  TERM AND TERMINATION

     5.1 The term of this Agreement shall be until the completion of the Study,
which is anticipated to be one (1) year from the Effective Date, unless
terminated in accordance with Section 5.2.

     5.2. Any party hereto shall have the right to terminate the Study and
this Agreement at any time upon thirty (30) days prior written notice thereof to
the other parties, except that any party may terminate this Agreement
immediately upon written notice to the other parties if necessary to protect the
health, welfare or safety of any Study subject.

     5.3 In the event of termination, the amount of the research grant by
Company to support the Study shall be appropriately prorated to allow General to
recover reasonable costs and noncancellable commitments incurred, including
without limitation, termination salary costs of any of General's employees
released as a result of such termination.

     5.4 The obligations of the parties under Sections 2, 3 and 6 shall survive
the termination or expiration of this Agreement.

SECTION 6: INDEMNIFICATION AND INSURANCE

     6.1 INDEMNIFICATION (a) Company shall indemnify, defend and hold harmless
General and its trustees, officers, medical and professional staff, employees,
and agents and their respective successors, heirs and assigns (the
"Indemnitees"), against any liability, damage, loss or expense (including
reasonable attorney's fees and expenses of litigation) incurred by or imposed
upon the Indemnitees or any one of them in connection with any claims, suits,
actions, demands or judgments arising out of any side effect, adverse reaction,
illness, or injury occurring to any person as a result of his or her involvement
in the Study.

                                       6
<PAGE>

         (b) Company's indemnification under (a) above shall not apply to any
liability, damage, loss or expense to the extent that it is directly
attributable to: (i) the negligent activities, reckless misconduct or
intentional misconduct of the Indemnitees; or (ii) failure of the Indemnitees to
adhere to the terms of the protocol for the Study.

         (c) Company agrees, at its own expense, to provide attorneys reasonably
acceptable to General to defend against any actions brought or filed against any
party indemnified hereunder with respect to the subject of the indemnity
contained herein, whether or not such actions are rightfully brought.

         (d) Company also agrees to reimburse General for the costs of the care
and treatment of any illness or injury to a subject resulting from his or her
participation in the Study to the extent that such costs are not covered by the
subject's medical or hospital insurance or governmental programs providing such
coverage.

     6.2 INSURANCE (a) Company shall, at its sole cost and expense, procure and
maintain commercial general liability insurance or equivalent self-insurance in
amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate.
Such commercial general liability insurance or equivalent self-insurance shall
provide contractual liability coverage for Company's indemnification under
Section 6.1 of this Agreement.

         (b) Company shall provide General with written evidence of such
insurance prior to the commencement of the Study. Company shall provide General
with written notice at least fifteen (15) days prior to the cancellation,
non-renewal or material change, in such insurance; if Company does not obtain
replacement insurance providing comparable coverage within such fifteen (15) day
period, General shall have the right to terminate this Agreement effective at
the end of such fifteen (15) day period without notice of any additional waiting
periods.

SECTION 7: MISCELLANEOUS

     7.1 The terms of this Agreement can be modified only by a writing which is
signed by General, Principal Investigator and Company.

     7.2 The provisions of this Agreement shall be interpreted under the laws of
the Commonwealth of Massachusetts, regardless of the choice of law rules of any
jurisdiction.

     7.3 No party to this Agreement may assign its obligations hereunder without
the prior written consent of the other parties.

     7.4 This Agreement constitutes the entire understanding between the
parties, and supersedes and replaces all prior agreements, understandings,
writings and discussions between the parties, with respect to the subject matter
of this Agreement.

                                       7
<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed as of the day and year first above written.

LASER PHOTONICS, INC.                 THE GENERAL HOSPITAL CORPORATION
                                      (Federal Tax ID No.: 042 697 983)

BY: /s/ Chaim Markheim            By:  /s/ Nikki J. Zapol
       --------------------------         ---------------
        Chain Markheim                     Nikki J. Zapol

TITLE:  COO/CFO                   TITLE: Director, Office of Corporate Sponsored
                                         Research and Licensing

DATE:   8/4/99                    DATE:  8/9/99

                                       8

<PAGE>

                      AMENDMENT TO THE AGREEMENT EFFECTIVE
                     JULY 27, 1999 BETWEEN LASER PHOTONICS,
                        THE GENERAL HOSPITAL CORPORATION,
                             AND DR. CHARLES TAYLOR

     Effective March 1, 2000, The General Hospital Corporation, a not-for-profit
corporation doing business as Massachusetts General Hospital, Fruit Street,
Boston, Massachusetts ("Hospital") Charles Taylor, MD, Department of Dematology,
Massachusetts General Hospital, Boston, Massachusetts 02114 ("Principal
Investigator") and Laser Photonics, Inc. a corporation having an office at 2431
Impala Drive, Carlsbad, CA 92008 ("Company") hereby amend the Clinical Trial
Agreement effective July 27, 1999 between Company, Hospital and Principal
Investigator pertaining to the study entitled "308 nm Excimir Laser for the
Treatment of Plaque Psoriasis (4MED/6MED)" ("Agreement") as follows:

1)   Paragraph 4.1 of the Agreement shall be replaced with the following:

     Company agrees to support this Study with a research grant of Two hundred
fourteen thousand, three hundred seventy-five dollars ($214,375), which includes
indirect costs in the amount of Forty-two thousand, eight hundred seventy-five
dollars ($42,875) computed at a rate of 25% of total direct costs, payable to
General as follows

     One hundred sixty-nine thousand, two hundred nineteen dollars ($169,219)
upon execution of the original Agreement (paid as of 8/99); Fifteen thousand,
eight hundred forty-three dollars and seventy-five cents ($15,843.75) of which
shall be transferred to cover costs incurred in the Laser Photonics "High
Fluence Study" upon execution of this Amendment;

     Seven thousand, four hundred six dollars ($7,406.00) upon enrollment of
twelve (12) subjects; and,

     Fifty-three thousand, five hundred ninety-three dollars and seventy-five
cents ($53,593.75) upon completion of a total of twenty (20) subjects and
submission of all completed case report forms.

     2.   The Agreement in all other respects shall remain in full force and
effect.

                                       1
<PAGE>

ACCEPTED AND AGREED TO:

LASER PHOTONICS, INC.                  THE GENERAL HOSPITAL CORPORATION

BY:  /s/ Jeffrey F. O'Donnell          BY:  /s/ Elizabeth L.S. Dana
   --------------------------------       --------------------------------
TITLE: CEO
                                       TITLE: Clinical Trial Agreement Associate
                                       Office of Corporate Sponsored Research
                                       and Licensing

DATE:                                  DATE:  3/17/00
     ------------------------------         ----------

                                      PRINCIPAL INVESTIGATOR

                                      BY:  /s/ Charles Taylor
                                         ----------------------------------
                                         Dr. Charles Taylor

                                      DATE: 3/13/00
                                           ------------

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]